Transmission risk and predictability of invasive meningococcal disease

Surveillance of Invasive Meningococcal Disease

Invasive meningococcal disease (IMD) is a nationally reportable disease in Canada. Since 1985, the Laboratory Centre for Disease Control (LCDC) has enhanced IMD surveillance to correlate case-by-case information provided by the provinces and territories with detailed laboratory studies done at the National Laboratory for Bacteriology at LCDC. This report provides information on IMD from 1 Janua...

Invasive meningococcal disease in childhood.

Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands

Invasive meningococcal disease (IMD) is a severe bacterial infectious disease with high mortality and morbidity rates worldwide. In recent years, industrialised countries have implemented vaccines targeting IMD in their National Immunisation Programmes (NIPs). In 2002, the Netherlands successfully implemented a single dose of meningococcal serogroup C conjugate vaccine at the age of 14 months a...

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine

Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Sixteen cases of meningococcal disease were identified in eculizumab recipients in the Uni...

Invasive meningococcal disease and HIV coinfection.

Three cases of meningococcal disease which occurred over a 3 year period in HIV-infected people living in the Wentworth Health Area of Sydney, Australia, are described. None of the 3 had ever received antiretroviral therapy which may, have contributed to development of invasive meningococcal disease.